A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome
Phase of Trial: Phase I/II
Latest Information Update: 11 Mar 2016
Price : $35 *
At a glance
- Drugs Angiotensin II (Primary)
- Indications Hepatorenal syndrome
- Focus Adverse reactions
- Sponsors La Jolla Pharmaceutical Company
- 09 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 09 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
- 09 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.